Ferrata Storti Foundation

SHERPA: Unknown

People

  1. Tallman
    Tallman
  2. Levine
    Levine
  3. Zelenetz
    Zelenetz
  4. Mauro
    Mauro
  5. Stein
    Stein
  6. Abdel-Wahab
    Abdel-Wahab
  7. Dogan
    Dogan
  8. Salles
    Salles
  9. Horwitz
    Horwitz
  10. Perales
    Perales

Groups

  1. Department of Medicine (296)
  2. Hematologic Malignancies, Division of (295)
  3. Center for Hematologic Malignancies (270)
  4. Adult Leukemia (107)
  5. Lymphoma (73)
  6. GSK Faculty (70)
  7. Executive Committee, Center for Hematologic Malignancies (60)
  8. Hematologic Malignancies Research (45)
  9. Sloan Kettering Institute Postdocs (44)
  10. Center for Molecular Imaging and Biotechnology (CMIB) (41)
Search Within
Formats
  1. Meeting Abstract (178)
  2. Journal Article (124)
  3. Research Letter (26)
  4. Editorial (17)
  5. Review (12)
  6. Correspondence (1)
  7. Guidelines (1)
Groups
  1. Department of Medicine (296)
  2. Hematologic Malignancies, Division of (295)
  3. Center for Hematologic Malignancies (270)
  4. Adult Leukemia (107)
  5. Lymphoma (73)
  6. GSK Faculty (70)

More Groups

People
  1. Carl Landgren (25)
  2. Martin Tallman (25)
  3. Andrew Zelenetz (24)
  4. Ross Levine (24)
  5. Michael Mauro (21)
  6. Anas Younes (16)

More People

Years
  1. 2025 (19)
  2. 2024 (23)
  3. 2023 (17)
  4. 2022 (20)
  5. 2021 (13)
  6. 2020 (18)

More Years

Publications
  1. Haematologica (355)
  2. Haematologica Meeting Reports (4)

Results (359)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Early death and intracranial hemorrhage prediction in acute promyelocytic leukemia: Validation of a risk score in a cohort from an international consortium treated with chemotherapy plus all-trans retinoic acid
    Research Letter

    Silva, W. F.; Kim, H. T.; Undurraga, M. S.; Navarro-Cabrera, J. R.; Salinas, V.; Muxi, P.; Melo, R. A. M.; Gloria, A. B. F.; Pagnano, K. B. B.; Nunes, E. C.; more...
    Haematologica (2025)

    Fulltext@MSK | Save
  • Loncastuximab in high-risk and heavily pretreated relapsed/refractory diffuse large B-cell lymphoma: A real-world analysis from 21 US centers
    Journal Article

    Zelikson, V.; Gurumurthi, A.; Sawalha, Y.; Annunzio, K.; Saha, A.; Dong, N.; Qualls, D.; Amoozgar, B.; Kahl, B.; Baird, J.; more...
    Haematologica (2025)

    Fulltext@MSK | Save
  • Predictors and implications of renal injury after CD19 chimeric antigen receptor T-cell therapy
    Journal Article

    Boardman, A. P.; Gutgarts, V.; Flynn, J. R.; Devlin, S. M.; Goldman, A.; Tomas, A. A.; Fein, J. A.; Slingerland, J. B.; Parascondola, A.; Lin, R. J.; more...
    Haematologica (2025)

    Fulltext@MSK | Save
  • Polytypic B cells, monotypic/monoclonal B-cell proliferations, and neoplastic T cells diverge from TET2-/ DNMT3A-mutant clonal hematopoiesis in follicular helper T-cell lymphomas
    Research Letter

    Lewis, N. E.; Petrova-Drus, K.; Sardana, R.; Huet, S.; Gao, Q.; Sethi, S.; Vanderbilt, C.; Xiao, W.; Roshal, M.; Baik, J.; more...
    Haematologica (2025)

    Fulltext@MSK | Save
  • Rituximab and lenalidomide for the treatment of relapsed or refractory indolent non-Hodgkin lymphoma: Real-life experience
    Journal Article

    Cassanello, G.; Drill, E.; Rivas-Delgado, A.; Okwali, M.; Isgor, I.; Caron, P. C.; Epstein-Peterson, Z.; Ghione, P.; Hamlin, P. A.; Lue, J. K.; more...
    Haematologica (2025)

    Fulltext@MSK | Save
  • Evaluating serum free light chain ratio as a biomarker in multiple myeloma
    Journal Article

    Akhlaghi, T.; Maclachlan, K.; Korde, N.; Mailankody, S.; Lesokhin, A. M.; Hassoun, H.; Lu, S. X.; Patel, D.; Shah, U. A.; Tan, C. R.; more...
    Haematologica (2025)

    Fulltext@MSK | Save
  • Challenges in defining the immune microenvironment in T-cell lymphoma
    Editorial

    Dogan, A.; Roshal, M.
    Haematologica (2025)

    Fulltext@MSK | Save
  • Help or hindrance? Rituximab maintenance and COVID
    Editorial

    Noy, A.
    Haematologica (2025)

    Fulltext@MSK | Save
  • Pirtobrutinib monotherapy in Bruton tyrosine kinase inhibitor-intolerant patients with B-cell malignancies: Results of the phase I/II BRUIN trial
    Journal Article

    Shah, N. N.; Wang, M.; Roeker, L. E.; Patel, K.; Woyach, J. A.; Wierda, W. G.; Ujjani, C. S.; Eyre, T. A.; Zinzani, P. L.; Alencar, A. J.; more...
    Haematologica (2025)

    Fulltext@MSK | Save
  • Prognostic impact of 'multi-hit' versus 'single-hit' TP53 alteration in patients with acute myeloid leukemia: Results from the Consortium on Myeloid Malignancies and Neoplastic Diseases
    Journal Article

    Badar, T.; Nanaa, A.; Atallah, E.; Shallis, R. M.; Craver, E. C.; Li, Z.; Goldberg, A. D.; Saliba, A. N.; Patel, A.; Bewersdorf, J. P.; more...
    Haematologica (2024)

    Fulltext@MSK | Save

    • Ferrata Storti Foundation – authorized name for: